SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Nevertheless, many of the preliminary studies conducted to date have reported encouraging results, and it is hoped that future studies of SGLT-2 inhibitors in patients with type 2 diabetes and NAFLD can provide robust evidence to confirm their therapeutic potential within this population.